The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
Open accessAbstract
Nucleoside-modified messenger RNA (mRNA)-lipid nanoparticles (LNPs) are the basis for the first two EUA (Emergency Use Authorization) COVID-19 vaccines. The use of nucleoside-modified mRNA as a pharmacological agent opens immense opportunities for therapeutic, prophylactic and diagnostic molecular interventions. In particular, mRNA-based drugs may specifically modulate immune cells, such as T lymphocytes, for immunotherapy of oncologic, infectious and other conditions. The key challenge, however, is that T cells are notoriously resistant to transfection by exogenous mRNA. Here, we report that conjugating CD4 antibody to LNPs enables specific targeting and mRNA interventions to CD4+ cells, including T cells. After systemic injection in mice, CD4-targeted radiolabeled mRNA-LNPs accumulated in spleen, providing ∼30-fold higher signal of reporter mRNA in T cells isolated from spleen as compared with non-targeted mRNA-LNPs. Intravenous injection of CD4-targeted LNPs loaded with Cre recombinase-encoding mRNA provided specific dose-dependent loxP-mediated genetic recombination, resulting in reporter gene expression in about 60% and 40% of CD4+ T cells in spleen and lymph nodes, respectively. T cell phenotyping showed uniform transfection of T cell subpopulations, with no variability in uptake of CD4-targeted mRNA-LNPs in naive, central memory, and effector cells. The specific and efficient targeting and transfection of mRNA to T cells established in this study provides a platform technology for immunotherapy of devastating conditions and HIV cure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 1×
“14 Moreover, mRNA-based therapeutics could offer gene-editing tools for treating viral infections and cancer or correcting genetic defects, such as knocking out the C-C chemokine receptor 5 (CCR5) gene for preventing HIV infection of T cells 15,16 or knocking out the programmed cell death-1…”
Self-citationKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationTherapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Self-citationTargeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
The Spleen in Local and Systemic Regulation of Immunity
Bronte, V., & Pittet, M. J. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.010 · Cited by 1,064
Maier, M. A., Jayaraman, M., Matsuda, S., Liu, J., Barros, S., Querbes, W., Tam, Y. K., Ansell, S. M., Kumar, V., Qin, J., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.124 · Cited by 625 · cited 1×
“0 is rapidly mixed with a solution of lipids dissolved in ethanol.(50) LNPs used in this study were similar in composition to those described previously,(50,51) which contain an ionizable cationic lipid (proprietary to Acuitas)/phosphatidylcholine/cholesterol/PEG-lipid (50:10:38.”
Self-citationA facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569
Self-citationLinkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells
Maugeri, M., Nawaz, M., Papadimitriou, A., Angerfors, A., Camponeschi, A., Na, M., Hölttä, M., Skantze, P., Johansson, S., Sundqvist, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12275-6 · Cited by 428
Engineered T Cell Therapy for Cancer in the Clinic
Zhao, L., & Cao, Y. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02250 · Cited by 410
Immunological and Toxicological Considerations for the Design of Liposomes
Inglut, C. T., Sorrin, A. J., Kuruppu, T., Vig, S., Cicalo, J., Ahmad, H., & Huang, H.-C. (2020) · Nanomaterials · doi:10.3390/nano10020190 · Cited by 371
Gene Therapy Leaves a Vicious Cycle
Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00297 · Cited by 347
Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes
Veiga, N., Goldsmith, M., Granot, Y., Rosenblum, D., Dammes, N., Kedmi, R., Ramishetti, S., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-06936-1 · Cited by 308 · cited 2×
“Veiga et al. 45 delivered mRNA in surface-modi fi ed LNPs to in fl ammatory Ly6C + leukocytes using their ASSET platform, which also employs monoclonal antibody targeting.”
Fenton, O. S., Kauffman, K. J., Kaczmarek, J. C., McClellan, R. L., Jhunjhunwala, S., Tibbitt, M. W., Zeng, M. D., Appel, E. A., Dorkin, J. R., Mir, F. F., et al. (2017) · Advanced Materials · doi:10.1002/adma.201606944 · Cited by 288
Gene Therapies for Cancer: Strategies, Challenges and Successes
Das, S. K., Menezes, M. E., Bhatia, S., Wang, X., Emdad, L., Sarkar, D., & Fisher, P. B. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24791 · Cited by 284
McKinlay, C. J., Benner, N. L., Haabeth, O. A., Waymouth, R. M., & Wender, P. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805358115 · Cited by 238
Parhiz, H., Shuvaev, V. V., Pardi, N., Khoshnejad, M., Kiseleva, R. Y., Brenner, J. S., Uhler, T., Tuyishime, S., Mui, B. L., Tam, Y. K., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.015 · Cited by 233
Self-citationSystemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles
Ramishetti, S., Kedmi, R., Goldsmith, M., Leonard, F., Sprague, A. G., Godin, B., Gozin, M., Cullis, P. R., Dykxhoorn, D. M., & Peer, D. (2015) · ACS Nano · doi:10.1021/acsnano.5b02796 · Cited by 210
Gene editing for immune cell therapies
Bailey, S. R., & Maus, M. V. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0137-8 · Cited by 203
Making CAR T Cells a Solid Option for Solid Tumors
Schmidts, A., & Maus, M. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02593 · Cited by 187
Marcos-Contreras, O. A., Greineder, C. F., Kiseleva, R. Y., Parhiz, H., Walsh, L. R., Zuluaga-Ramirez, V., Myerson, J. W., Hood, E. D., Villa, C. H., Tombacz, I., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912012117 · Cited by 185
Self-citationmRNA mediates passive vaccination against infectious agents, toxins, and tumors
Thran, M., Mukherjee, J., Pönisch, M., Fiedler, K., Thess, A., Mui, B. L., Hope, M. J., Tam, Y. K., Horscroft, N., Heidenreich, R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707678 · Cited by 182 · cited 1×
“To confirm the targeting efficiency of the CD4-targeted mRNALNP platform with LNP formulations other than ALC-0307 LNPs, we applied the same antibody conjugation strategy on the Acuitas LNP formulation containing the ionizable lipid 0315 (ALC-0315 LNP), which is the LNP formulation in the recently US Food and Drug Adm…”
Self-citationKarikó, K., & Weissman, D. (2007) · PubMed · Cited by 179
Self-citationDidigu, C. A., Wilen, C. B., Wang, J., Duong, J., Secreto, A. J., Danet-Desnoyers, G. A., Riley, J. L., Gregory, P. D., June, C. H., Holmes, M. C., et al. (2014) · Blood · doi:10.1182/blood-2013-08-521229 · Cited by 159
Mandl, J. N., Liou, R., Klauschen, F., Vrisekoop, N., Monteiro, J. P., Yates, A. J., Huang, A. Y.-C., & Germain, R. N. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211717109 · Cited by 156
Pitcher, C., Höning, S., Fingerhut, A., Bowers, K., & Marsh, M. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.3.677 · Cited by 146
Recent updates on cancer immunotherapy
Liu, M., & Guo, F. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby011 · Cited by 145
mRNA as novel technology for passive immunotherapy
Schlake, T., Theß, A., Thran, M., & Jordan, I. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2935-4 · Cited by 143
Foster, J., Choudhari, N., Perazzelli, J., Storm, J., Hofmann, T. J., Jain, P., Storm, P. B., Pardi, N., Weissman, D., Waanders, A. J., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.145 · Cited by 141
Self-citationKarpinski, J., Hauber, I., Chemnitz, J., Schäfer, C., Paszkowski‐Rogacz, M., Chakraborty, D., Beschorner, N., Hofmann-Sieber, H., Lange, U. C., Grundhoff, A. T., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3467 · Cited by 140
Liu, Z., Chen, S., Jin, X., Wang, Q., Yang, K., Li, C., Xiao, Q., Hou, P., Liu, S., Wu, S., et al. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0174-2 · Cited by 131
The Future of Immunotherapy: A 20-Year Perspective
Wraith, D. C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01668 · Cited by 111
The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy
Foster, J., Barrett, D. M., & Karikó, K. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.018 · Cited by 109
Mathematical Modeling Reveals Kinetics of Lymphocyte Recirculation in the Whole Organism
Ganusov, V. V., & Auerbach, J. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003586 · Cited by 103
Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes
Veiga, N., Diesendruck, Y., & Peer, D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.002 · Cited by 79
CAR T‐cell immunotherapy: The path from the by‐road to the freeway?
Whilding, L. M., & Maher, J. F. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.012 · Cited by 63
Efficient nonviral gene delivery into primary lymphocytes from rats and mice
Goffinet, C., & Keppler, O. T. (2006) · The FASEB Journal · doi:10.1096/fj.05-4651fje · Cited by 60
Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes
Mizrahy, S., Hazan‐Halevy, I., Dammes, N., Landesman‐Milo, D., & Peer, D. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.001 · Cited by 60
T‐lymphocyte subset distribution in human spleen
Langeveld, M., Gamadia, L. E., & ten Berge, I. J. M. (2006) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01626.x · Cited by 43
The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective
Junghans, R. P. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2016.82 · Cited by 35
Vascular Accessibility of Endothelial Targeted Ferritin Nanoparticles
Khoshnejad, M., Shuvaev, V. V., Pulsipher, K. W., Dai, C., Hood, E. D., Arguiri, E., Christofidou‐Solomidou, M., Dmochowski, I. J., Greineder, C. F., & Muzykantov, V. R. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00641 · Cited by 34
Self-citationAdvances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles
Ramishetti, S., Landesman‐Milo, D., & Peer, D. (2016) · Journal of drug targeting · doi:10.3109/1061186x.2016.1172587 · Cited by 33
Peer, D. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.06.029 · Cited by 25
Production of recombinant immunotherapeutics for anticancer treatment: The role of bioengineering
Pranchevicius, M.-C. S., & Vieira, T. R. (2013) · Bioengineered · doi:10.4161/bioe.24666 · Cited by 24
Cao, S., Jiang, Y., Levy, C., Hughes, S. M., Zhang, H., Hladik, F., & Woodrow, K. A. (2017) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36315 · Cited by 20
T Cell Co-Stimulation: Inhibition of Immunosuppression?
Sundqvist, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00974 · Cited by 13
Panezai, J., Bergdahl, E., & Sundqvist, K. (2017) · Immunology · doi:10.1111/imm.12770 · Cited by 11
Immunotherapy with Genetically Modified T Cells
Schultz, L. M., & Mackall, C. L. (2018) · Wiley eBooks · doi:10.1002/9781118684535.ch8 · Cited by 2
Cited by
CAR T cells produced in vivo to treat cardiac injury
Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2022) · Science · doi:10.1126/science.abm0594 · Cited by 1,400
Self-citationThe role of lipid components in lipid nanoparticles for vaccines and gene therapy
Hald Albertsen, C., Kulkarni, J. A., Witzigmann, D., Lind, M., Petersson, K., & Simonsen, J. B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114416 · Cited by 1,185
The clinical progress of mRNA vaccines and immunotherapies
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823
Dilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 671
Unlocking the promise of mRNA therapeutics
Rohner, E., Yang, R., Foo, K. S., Goedel, A., & Chien, K. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01491-z · Cited by 612
Metadata
- Authors
- Tombácz, I., Laczkó, D., Shahnawaz, H., Muramatsu, H., Natesan, A., Yadegari, A., Papp, T. E., Alameh, M.-G., Shuvaev, V., Mui, B. L., Tam, Y. K., Muzykantov, V., Pardi, N., Weissman, D., & Parhiz, H.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 29
- Issue
- 11
- Pages
- 3293-3304
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W3166016270
- Cited by
- 296
- References
- 50
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.